Prednisone, lupus activity, and permanent organ damage

Area of Science:

• Rheumatology
• Clinical Pharmacology

Background:

• Systemic lupus erythematosus (SLE) is a chronic autoimmune disease requiring immunosuppressive therapy.
• Corticosteroids, particularly prednisone, are a cornerstone of SLE management but are associated with potential long-term toxicities.
• Quantifying the risk of irreversible organ damage from prednisone in SLE is essential for treatment optimization.

Purpose of the Study:

• To evaluate the association between cumulative prednisone dosage and the incidence of permanent organ damage in patients with SLE.
• To differentiate the effects of prednisone from disease activity using advanced statistical modeling.

Main Methods:

• A cohort of 525 incident SLE patients was followed longitudinally.
• Data on clinical activity, laboratory results, and treatments were collected at each visit.
• A marginal structural model was employed to estimate the hazard ratio of organ damage associated with varying cumulative average prednisone doses, adjusting for time-dependent confounding.

Main Results:

• Compared to non-prednisone users, the hazard ratio for organ damage increased with higher cumulative prednisone doses.
• Hazard ratios ranged from 1.16 (0-180 mg/month) to 2.51 (>540 mg/month).
• Standard Cox regression models overestimated these risks, highlighting the importance of the chosen methodology.

Conclusions:

• Low cumulative doses of prednisone (up to 540 mg/month) did not appear to substantially increase the risk of irreversible organ damage in SLE patients.
• These findings support the judicious use of low-dose prednisone in managing SLE.
• Further research may explore optimal prednisone tapering strategies to minimize long-term risks.